As Synthetic Urine Sales Approach $1 Billion Annually, Validity Diagnostics Showcases Patented Detection Technology at SOFT-TIAFT 2026
NEW YORK, NY, UNITED STATES, August 10, 2026 /EINPresswire.com/ — Validity Diagnostics (VDx) of Branford, FL, a leader in urine drug test validity solutions, will showcase the second-generation urine specimen validity reagents at the SOFT–TIAFT 2026 Joint Meeting in Chicago, IL on September 19-24, 2026. The company will highlight how advanced validity testing can help Fortune 500 companies, federal and state government employers, federal and state drug courts / probation offices and drug testing laboratories combat the growing threat of workplace urine drug test subversion.
As the submission of synthetic and adulterated urine continues to rise, many drug testing programs face a serious challenge – maintaining urine sample integrity. The Validity Diagnostics True Essentials Panel, which includes Oxidant History, True Urine LD and True Urine SD reagents, provides drug testing laboratories with dependable, science-backed tools to detect synthetic and/or adulterated urine.
“Workplace urine drug testing is only as dependable as the integrity of the urine sample” says Donna Suggs, CEO of Validity Diagnostics. “We are seeing increased sophistication in urine sample subversion, and our products are specifically designed to help drug testing laboratories detect these threats before they compromise compliance or safety in the workplace.”
“The drug testing industry has been operating on a false sense of security for decades” says Garet Rembert, Co-Founder and VP of Sales, Validity Diagnostics. “Synthetic urine is a billion-dollar industry built specifically to defeat the tests we rely on, and peer-reviewed research from the U.S. military and RTI International has confirmed that standard validity testing cannot detect it. The science to solve this problem exists. VDx patented technology has proven in multiple independent studies that synthetic urine can be reliably identified when laboratories use the right tools. The time to adapt is now.”
Independent research, including the 2025 study by Franke et. al. from Jena University Hospital, GERMANY and a 2025 study from RTI International in Research Triangle Park, North Carolina, demonstrated that the Validity Diagnostics True Urine LD and True Urine SD reagents outperformed conventional validity tests when identifying synthetic urine. These findings confirm that traditional detection methods are no longer sufficient in today’s urine testing environment where synthetic urine products continue to evolve.
About Validity Diagnostics
Validity Diagnostics (VDx) is an industry leader in laboratory innovation and validity testing for urine drug screening. The VDx True Essentials Panel, featuring True Urine LD, True Urine SD, and Oxidant History, helps laboratories and collection sites detect synthetic and adulterated urine samples before the urine samples are tested for drugs. VDx partners with reference laboratories, hospital laboratories, and program administrators nationwide to promote urine drug testing integrity and reliability.
Ricky P Bateh, PhD
Validity Diagnostics
+1 904-448-3168
rick@vdxcares.com
Legal Disclaimer:
EIN Presswire provides this news content “as is” without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Media gallery
